Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma.
Hsin-Yu KuoMeng-Zhi HanChih-Hsiang LiaoYih-Jyh LinChung-Teng WangShang-Hung ChenTing-Tsung ChangPo-Jun ChenSheng-Hsiang LinChiung-Yu ChenChiao-Hsiung ChuangI-Chin WuJuei-Seng WuTzu-Chun HongMing-Tsung HsiehYang-Cheng LeeHung-Tsung WuHong-Ming TsaiPublished in: Pharmaceutics (2022)
Both pembrolizumab and nivolumab had significant effects for HCC therapy, and pembrolizumab had a significant survival benefit as compared with nivolumab.